Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

NN3201

Stage Phase 1

Sponsor Novelty Nobility

Modality antibody-drug conjugate

Class KIT-directed ADC

Target KIT (TEC-0117)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/

ClinicalTrials.gov API v2 records pulled 2026-10-27 (raw/ctgov/; registry fields as entered by sponsors). Search for adenoid cystic carcinoma returned 171 studies; none is an ACC-specific Phase 3. Records read: ACCURACY NCT03691207 (Ayala, completed, n 87, results posted 01.31.2024); CB-103 NCT03422679 (Cellestia, terminated for business reasons, n 79); CB-103 plus lenvatinib or abemaciclib NCT05774899 (PCD 2027-06-01); RGT-61159 NCT06462183 (Phase 1, active not recruiting, PCD 2027-12, 105 est.; includes a randomized two-dose optimization cohort and a lenvatinib combination arm); REM-422 NCT06118086 (Phase 1/2 ARIA, recruiting, PCD 2027-09-30, 125 est.); Emi-Le NCT05377996 (Phase 1/2, sponsor listed as Day One Biopharmaceuticals, PCD 2027-02, 360 est.); puxitatug samrotecan NCT07162480 (MD Anderson, PCD 2029-12-31, 28 est.); sacituzumab tirumotecan NCT07521670 (Singapore, not yet recrui

Brief source A3

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06805825

A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT06805825

Registry NCT06805825

Phase Phase 1

Status Recruiting

Enrollment 67

Start 2025-02-03

Primary completion 2027-08-30

Study completion 2027-12-31

Catalyst Primary completion. 08.30.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.